Published on April 17, 2026
BioLamina, a Stockholm-based biotech firm, has been a key player in supplying laminin-based cell culture matrices. These matrices are crucial for stem cell therapy developers who rely on them to grow cells effectively in laboratories. Until now, BioLamina’s production capacity has limited its ability to meet growing demand.
The European Investment Bank (EIB) has stepped in with a €20 million loan aimed at scaling BioLamina’s operations. This funding will enhance their production of laminin technologies and support the development of animal-free drug safety testing methods. This shift comes at a time when alternatives to animal testing are gaining strong regulatory backing.
With the new funding, BioLamina plans to ramp up its output significantly. This move is expected to allow the company to better serve its global clientele and keep pace with the increasing demand for efficient and ethical cell culture solutions. It positions them to expand their market influence while adhering to innovative standards in biomanufacturing.
The consequences of this loan extend beyond BioLamina. capabilities, the company could play a critical role in accelerating the development of cell therapies. Moreover, their focus on animal-free methodologies could contribute to a wider industry shift toward more sustainable practices in drug development.
Related News
- GitHub Launches Free Game to Tackle AI Security Vulnerabilities
- Zoom Introduces Human Verification to Combat AI Imposters
- Quantum Threat Accelerates Race for Cryptographic Security
- Good Omens Season 3 Trailer Teases Epic Conclusion for Beloved Series
- Foreo Offers Major Discounts to Elevate Skincare Routines
- ChatGPT Streamlines Data Analysis for Businesses